Author

Pascal Hammel 1

1 Hôpital Beaujon,Clic

APPROPRIATENESS OF PANCREATIC SURGERY IN HIGH-RISK INDIVIDUALS FOR FAMILIAL PANCREATIC DUCTAL ADENOCARCINOMA

Louis de Mestier, Marie Muller, Jérôme Cros, Marie-Pierre Vullierme, Dewi Vernerey, Frédérique Maire, Safi Dokmak, Vinciane Rebours, Alain Sauvanet, Philippe Lévy, Pascal Hammel

COMPARATIVE ANALYSIS BETWEEN SENDAI GUIDELINES AND THE EUROPEAN EXPERTS CONSENSUS STATEMENT ON BD-IPMN OF THE PANCREAS.

Enrique Perez-Cuadrado-Robles, Vinciane Rebours, Jérôme Cros, Marie-Pierre Vullierme, Frédérique Maire, Olivia Hentic, Pascal Hammel, Alain Sauvanet, Philippe Lévy, Philippe Ruszniewski

COMPARISON OF CHEMORADIOTHERAPY (CRT) AND CHEMOTHERAPY (CT) IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC) CONTROLLED AFTER 4 MONTHS OF GEMCITABINE WITH OR WITHOUT ERLOTINIB: FINAL RESULTS OF THE INTERNATIONAL PHASE III LAP 07 STUDY

Pascal Hammel, Florence Huguet, David Goldstein, Bengt Glimelius, Pascal Artru, Ivan Borbath, Jenny Shannon, Thierry André, Christophe Louvet, Jean-Luc Van Laethem

FEATURES PREDICTING MALIGNANCY IN BRANCH DUCT INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS

Enrique Robles, Marie-Pierre Vullierme, Nelly Muller, Vinciane Rebours, Pascal Hammel, Alain Aubert, Philippe Lévy, Philippe Ruszniewski

POSTOPERATIVE RECURRENCE IN PATIENTS OPERATED ON FOR BENIGN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (IPMN)

Oivier Roux, Marie-Pierre Vullierme, Safi Dokmak, Sébastien Gaujoux, Beatrice Aussilhou, Vinciane Rebours, Olivia Hentic-Dhomé, Maxime Palazzo, Laurent Palazzo, Alain Aubert, Anne Couvelard, Pascal Hammel, Philippe Lévy, Philippe Ruszniewski

Screening for pancreatic cancer: Who and how?

Pascal Hammel

Targeted therapies of pancreatic endocrine tumors a new therapeutic era?

Pascal Hammel

Item 1 - 7 / 21
1
2 3